Department of Psychiatry, Kwai Chung Hospital, 3-15 Kwai Chung Hospital Road, Hong Kong, China.
Department of Psychiatry, Queen Mary Hospital, Hong Kong, China.
Psychiatr Q. 2020 Dec;91(4):1225-1247. doi: 10.1007/s11126-020-09822-6.
Repetitive transcranial magnetic stimulation (rTMS) is effective in treating unipolar depression. However, the efficacy of rTMS in bipolar disorder (BD) is unclear. This meta-analysis aimed to examine the efficacy and tolerability of rTMS for both depressive and manic phases in BD.
MEDLINE, EMBASE, PsycINFO, CENTRAL databases were searched for controlled trials on treatment of BD with rTMS. Primary outcomes included changes in depression or mania scores, response and remission rates. Secondary outcomes included quality of life and functioning assessment. We used random-effects model, Hedge's g, risk differences (RDs) and the number needed to treat (NNT).
Eleven randomized sham-controlled studies were included, with a total of 345 patients with BD (bipolar depression = 257, mania = 86, mixed affective = 2). Trials of rTMS in bipolar depression (N = 8) demonstrated small but significant improvement in depression scores [standardized mean difference = 0.302, p < 0.05], compared to control group. Furthermore, rTMS brought a higher remission rate than sham-controls [RD = 0.104 ± 0.044, p < 0.05, NNT = 10; and a trend of greater response rate [RD = 0.074 ± 0.039, p = 0.06]. Results were inconclusive for effect of rTMS in mania. In both depressive and manic groups, no serious adverse events were reported. Risk of treatment-emergent mania appeared low.
There was limited number of eligible primary studies, with variable randomization procedures.
rTMS appears safe and effective in treating bipolar depression. More stringent RCTs are necessary for concrete conclusion about efficacy in mania.
重复经颅磁刺激(rTMS)在治疗单相抑郁方面有效。然而,rTMS 在双相障碍(BD)中的疗效尚不清楚。本荟萃分析旨在研究 rTMS 对 BD 的抑郁和躁狂期的疗效和耐受性。
检索 MEDLINE、EMBASE、PsycINFO、CENTRAL 数据库中关于 rTMS 治疗 BD 的对照试验。主要结局包括抑郁或躁狂评分的变化、反应率和缓解率。次要结局包括生活质量和功能评估。我们使用随机效应模型、Hedge's g、风险差异(RD)和需要治疗的人数(NNT)。
共纳入 11 项随机假对照研究,共有 345 例 BD 患者(双相抑郁=257 例,躁狂=86 例,混合性情感障碍=2 例)。rTMS 治疗双相抑郁的试验(n=8)显示,与对照组相比,抑郁评分有较小但有统计学意义的改善[标准化均数差=0.302,p<0.05]。此外,rTMS 带来的缓解率高于假对照[RD=0.104±0.044,p<0.05,NNT=10;并且有更高反应率的趋势[RD=0.074±0.039,p=0.06]。rTMS 对躁狂的疗效结果不确定。在抑郁和躁狂组中,均未报告严重不良事件。出现治疗相关性躁狂的风险似乎较低。
合格的主要研究数量有限,且随机化程序存在差异。
rTMS 治疗双相抑郁安全有效。需要更严格的 RCT 来确定 rTMS 治疗躁狂的疗效。